Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Siremadlin - Novartis Oncology

Drug Profile

Siremadlin - Novartis Oncology

Alternative Names: HDM-201; NVP-HDM201

Latest Information Update: 28 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Novartis; Novartis Oncology
  • Class Antineoplastics; Chlorobenzenes; Imidazoles; Pyridines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Liposarcoma; Myelofibrosis
  • Phase I Acute myeloid leukaemia; Colorectal cancer; Haematological malignancies; Myelodysplastic syndromes; Solid tumours; Uveal melanoma
  • Preclinical Cancer

Most Recent Events

  • 09 Jan 2020 Novartis withdraws a phase I/II trial in Acute myeloid (Combination therapy, Second-line therapy or greater, First-line therapy) leukaemia in Israel andGermany, prior to enrolment as the study design may not be optimal given the changing Acute myeloid leukaemia treatment landscape (NCT03760445)
  • 16 Oct 2019 Novartis completes a phase I/II trial in Liposarcoma (Combination therapy, Metastatic disease, Second-line therapy or greater) in Canada, France, Germany, Singapore, Spain and Taiwan (NCT02343172) (EudraCT2014-003604-75)
  • 09 Oct 2019 Centre Leon Berard plans the phase II MegaMOST trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in France (ET19-073; NCT04116541; EudraCT2019-001494-88)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top